Skip to main content

Vulvovaginitis

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Matinas Biopharma
Matinas BiopharmaBEDMINSTER, NJ
1 program
1
Oral Encochleated Amphotericin BPhase 21 trial
Active Trials
NCT02971007Completed137Est. May 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Matinas BiopharmaOral Encochleated Amphotericin B

Clinical Trials (1)

Total enrollment: 137 patients across 1 trials

NCT02971007Matinas BiopharmaOral Encochleated Amphotericin B

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Start: Nov 2016Est. completion: May 2017137 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.